Synthetic Genomics CEO and leadership

Dr. Fetzer has served as CEO and Board Member of Synthetic Genomics since November 2014. Previously, Dr. Fetzer served as President and CEO of Cerulean Pharma Inc. for five years, a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly traded clinical development stage company with a pipeline of product candidates. Prior to Cerulean Pharma, Dr. Fetzer served for five years in a variety of positions of increasing responsibility at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Corporate Development and Research & Development. Dr. Fetzer began his career at the Boston Consulting Group (BCG), a global leading management consulting firm, where he advanced over nine years from Consultant to Project Leader, Principal, and ultimately Partner and Managing Director.

Dr. Hamilton O. Smith co-founded Synthetic Genomics, Inc. in 2005 and serves as it's Co-Chief Scientific Officer. Dr. Smith serves as a Scientific Director of the Institute of Biological Energy Alternatives(IBEA) and Scientific Director of Synthetic Biology & Biological Energy Groups at the Venter Institute. He served as an Executive Vice President at Synthetic Genomics, Inc. He served as a Founder and Senior Director of DNA Resources of Celera Genomics and participated in the sequencing of the genomes of the fruit fly, mosquito, mouse and human. Previously, Dr. Smith served as the head of faculty and professor of molecular biology and genetics of the Johns Hopkins University School of Medicine. He was a Co-Founder and collaborated with The Institute for Genome Research (TIGR) to sequence the genome of H. influenza, archaea bacteria, and other bacteria. Dr. Smith is widely considered one of the experts in DNA library construction and DNA manipulation techniques. He serves as the Chairman and Member of Scientific Advisory Board of Metabolon Inc. Dr. Smith serves as a Member of Scientific Advisory Board at U.S. Genomics, Inc. and Excel Medical Ventures. He serves as a Director of Sunol Molecular Corporation. Dr. Smith was a Member of Scientific Advisory Board at Intercell Biomedical Research & Development AG until February 2006.

Doug Miller is a Chief Financial Officer at Synthetic Genomics.

About Jon is a Jon Getzinger, Chief Sales and Marketing Officer, Genovia Bio Division at Synthetic Genomics. He works or has worked at Ocean Nutrition Canada. About attended University of Michigan.

Fernanda Coelho is a Chief Business Development Officer at Synthetic Genomics. She works or has worked at Accenture and BP.

Dr. Hamilton O. Smith co-founded Synthetic Genomics, Inc. in 2005 and serves as it's Co-Chief Scientific Officer. Dr. Smith serves as a Scientific Director of the Institute of Biological Energy Alternatives(IBEA) and Scientific Director of Synthetic Biology & Biological Energy Groups at the Venter Institute. He served as an Executive Vice President at Synthetic Genomics, Inc. He served as a Founder and Senior Director of DNA Resources of Celera Genomics and participated in the sequencing of the genomes of the fruit fly, mosquito, mouse and human. Previously, Dr. Smith served as the head of faculty and professor of molecular biology and genetics of the Johns Hopkins University School of Medicine. He was a Co-Founder and collaborated with The Institute for Genome Research (TIGR) to sequence the genome of H. influenza, archaea bacteria, and other bacteria. Dr. Smith is widely considered one of the experts in DNA library construction and DNA manipulation techniques. He serves as the Chairman and Member of Scientific Advisory Board of Metabolon Inc. Dr. Smith serves as a Member of Scientific Advisory Board at U.S. Genomics, Inc. and Excel Medical Ventures. He serves as a Director of Sunol Molecular Corporation. Dr. Smith was a Member of Scientific Advisory Board at Intercell Biomedical Research & Development AG until February 2006.

Dr. Fetzer has served as CEO and Board Member of Synthetic Genomics since November 2014. Previously, Dr. Fetzer served as President and CEO of Cerulean Pharma Inc. for five years, a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly traded clinical development stage company with a pipeline of product candidates. Prior to Cerulean Pharma, Dr. Fetzer served for five years in a variety of positions of increasing responsibility at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Corporate Development and Research & Development. Dr. Fetzer began his career at the Boston Consulting Group (BCG), a global leading management consulting firm, where he advanced over nine years from Consultant to Project Leader, Principal, and ultimately Partner and Managing Director.